AnHeart Therapeutics
Director of Thoracic Oncology, Joyce Zeff Chair in Lung Cancer Research, University of Colorado Cancer Center.
Dr. David Ross Camidge is the Director of Thoracic Oncology at the University of Colorado. His focus is on Thoracic Malignancies and Developmental Therapeutics (Phase 1 studies). In 2012, he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a “Luminary in the quest to eradicate lung cancer.” In 2013, Dr. Camidge became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being “one of the leading minds in lung cancer today.” In 2015, he became the inaugural recipient of the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center. Dr. Camidge is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium and a member of the National Comprehensive Cancer Network Lung Cancer Committee.
Dr Camidge’s main areas of clinical and research interest are thoracic malignancies and developmental therapeutics. The discoveries he and the Colorado team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 250 academic publications, including in the Journal of Thoracic Oncology, Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He has presented his work at numerous national and international meetings.
Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado.
This person is not in the org chart
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.